DEA Notice: CalCog Inc. Seeks to Import Schedule I Substances for Clinical Trials

You might care about this because the Drug Enforcement Administration, or DEA, has announced an application from a company called CalCog Inc. This company wants to become a registered importer of certain controlled substances. Specifically, CalCog Inc. has applied to import Lysergic acid diethylamide, also known as LSD, 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, and Psilocyn. These substances are all classified as Schedule I controlled substances. This means they are considered to have a high potential for abuse and no currently accepted medical use, though research is changing perceptions. CalCog Inc. states its plan is to import these substances solely as dosage units for clinical trials. This is a very important detail. The registration, if approved, would not allow the company to import these drugs for any other purpose. This notice from the DEA also opens a period for public comments. Certain manufacturers and applicants can submit their comments or objections to this proposed registration. They can also ask for a hearing on the application. The deadline for these submissions is July 8, 2026. This process ensures transparency and allows stakeholders to voice their opinions on such a specialized application involving highly regulated substances. The document makes it clear that authorization will not allow importing these drugs for commercial sale, even if they are FDA-approved or not. What makes this notice particularly interesting is the specific list of controlled substances CalCog Inc. intends to import. All of them, including LSD, DMT, and Psilocyn, are Schedule I drugs. Historically, these substances have faced very strict regulations due to their classification. However, there has been a growing interest in their potential therapeutic uses, particularly in mental health research, leading to an increase in clinical trials. This application by CalCog Inc. highlights this shift. The fact that the company's import plan is strictly limited to "dosage units for clinical trials only" is a key point. This means the DEA is considering allowing the import of these substances for scientific study, not for general public access or commercial distribution. This distinction is crucial in the regulatory framework for controlled substances. It shows a careful approach to allowing research while maintaining control over drugs that are otherwise highly restricted. The notice clearly states that no other activities for these drug codes are permitted under this registration. This helps ensure the substances are used only for their stated research purpose. The tight controls ensure that the substances are not diverted for illicit use, which is a constant concern with Schedule I drugs. The DEA is careful to explain that commercial sale is not part of this approval. Several groups of people would find this legal document very interesting. First, medical researchers and pharmaceutical companies working on mental health treatments would pay close attention. Especially those looking into psychedelic-assisted therapies. This notice directly affects their ability to source materials for studies. Second, legal and regulatory professionals specializing in drug policy and controlled substances will find this important. It provides a real-world example of the DEA's process for handling import applications for Schedule I drugs. Third, patient advocacy groups and individuals interested in new treatment options for conditions like depression, anxiety, or PTSD might also follow this development. These substances are being studied for potential benefits in these areas. Fourth, ethicists and public policy experts concerned with the responsible conduct of research involving controlled substances would be interested. They would watch how these applications are handled. Finally, the general public interested in the evolving legal status and medical research of substances like LSD and DMT would find this notice relevant. It represents a step in the process of bringing these substances from illicit status to a carefully controlled research environment.